Mark Breidenbach
Stock Analyst at Oppenheimer
(1.64)
# 3,145
Out of 4,734 analysts
63
Total ratings
30.65%
Success rate
-0.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Breidenbach
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Maintains: Outperform | $27 → $30 | $19.14 | +56.74% | 4 | Sep 4, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $14 → $13 | $1.82 | +614.29% | 5 | May 21, 2024 | |
| EPIX ESSA Pharma | Reiterates: Outperform | $17 | $1.75 | +871.43% | 5 | Dec 13, 2023 | |
| ARVN Arvinas | Reiterates: Outperform | $95 | $18.05 | +426.32% | 6 | Aug 9, 2023 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $2.02 | +1,137.62% | 3 | Aug 8, 2023 | |
| CUE Cue Biopharma | Assumes: Outperform | $10 | $1.31 | +663.36% | 6 | Jun 26, 2023 | |
| MCRB Seres Therapeutics | Assumes: Outperform | $12 | $0.77 | +1,463.72% | 4 | Jun 26, 2023 | |
| BLRX BioLineRx | Reiterates: Outperform | $4 | $0.10 | +3,840.89% | 1 | May 25, 2023 | |
| CGEN Compugen | Maintains: Outperform | $8 → $7 | $2.25 | +211.11% | 7 | May 16, 2023 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $36 → $32 | $1.53 | +1,991.50% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $13 | $0.22 | +5,825.25% | 3 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $15 | $5.91 | +153.81% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $120 | $1.46 | +8,119.18% | 4 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $23 | $1.14 | +1,917.54% | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $225 → $195 | $5.55 | +3,413.51% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2,700 | $8.35 | +32,235.33% | 3 | Dec 13, 2019 |
Nurix Therapeutics
Sep 4, 2024
Maintains: Outperform
Price Target: $27 → $30
Current: $19.14
Upside: +56.74%
Allogene Therapeutics
May 21, 2024
Maintains: Outperform
Price Target: $14 → $13
Current: $1.82
Upside: +614.29%
ESSA Pharma
Dec 13, 2023
Reiterates: Outperform
Price Target: $17
Current: $1.75
Upside: +871.43%
Arvinas
Aug 9, 2023
Reiterates: Outperform
Price Target: $95
Current: $18.05
Upside: +426.32%
Immuneering
Aug 8, 2023
Reiterates: Outperform
Price Target: $25
Current: $2.02
Upside: +1,137.62%
Cue Biopharma
Jun 26, 2023
Assumes: Outperform
Price Target: $10
Current: $1.31
Upside: +663.36%
Seres Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $12
Current: $0.77
Upside: +1,463.72%
BioLineRx
May 25, 2023
Reiterates: Outperform
Price Target: $4
Current: $0.10
Upside: +3,840.89%
Compugen
May 16, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $2.25
Upside: +211.11%
Caribou Biosciences
Mar 10, 2023
Maintains: Outperform
Price Target: $36 → $32
Current: $1.53
Upside: +1,991.50%
Mar 3, 2023
Maintains: Outperform
Price Target: $15 → $13
Current: $0.22
Upside: +5,825.25%
Mar 1, 2023
Maintains: Outperform
Price Target: $25 → $15
Current: $5.91
Upside: +153.81%
Oct 18, 2022
Maintains: Outperform
Price Target: $90 → $120
Current: $1.46
Upside: +8,119.18%
Apr 26, 2021
Initiates: Outperform
Price Target: $23
Current: $1.14
Upside: +1,917.54%
May 12, 2020
Maintains: Outperform
Price Target: $225 → $195
Current: $5.55
Upside: +3,413.51%
Dec 13, 2019
Upgrades: Outperform
Price Target: $2,700
Current: $8.35
Upside: +32,235.33%